Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy.

Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the advantages and challenges of this life-changing therapy, including its long-term effects, while addressing patient concerns related to safety and accessibility. Finally, he provides a glimpse into the future of gene therapy.

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Frank Leebeek

If you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Program on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe